Biogen Shares Rise Thirty-Eight Percent After Alzheimer's Product Approval
Food and Drug Administration Sanitary Inspection (FDA) supported the introduction of the Aduhelm product, which was developed by Biogen (Nasdaq: BIIB). Aduhelm - 1st for about 20 years approved product, slowing down?? cognitive decline in people with Alzheimer's disease.